In the last trading session, 3,462,599 shares of the Zynerba Pharmaceuticals, Inc.(NASDAQ:ZYNE) were traded, and its beta was 2.98. Most recently the company’s share price was $4.91, and it changed around -$0.51 or -0.09% from the last close, which brings the market valuation of the company to $144.55 Million. ZYNE currently trades at a discount to its 52-week high of $9, offering almost -83.3% off that amount. The share price’s 52-week low was $2.55, which indicates that the current value has risen by an impressive 48.07% since then. We note from Zynerba Pharmaceuticals, Inc.’s average daily trading volume that its 10-day average is 6.58 Million shares, with the 3-month average coming to 5.09 Million.
Zynerba Pharmaceuticals, Inc. stock received a consensus recommendation rating of Overweight, based on a mean score of 2. If we narrow it down even further, the data shows that none out of 7 analysts rate the stock as a Sell; another but none rate it as Overweight. Among the rest, 2 recommended ZYNE as a Hold, whereas 5 deemed it a Buy, and no one rated it as Underweight. Zynerba Pharmaceuticals, Inc. is expected to report earnings per share of -$0.33 for the current quarter.
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE): Trading Information
Although ZYNE has showed a red trend with a performance of -9.41% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of $6.30- on Thursday, Feb 18 increased the stock’s daily price by 22.06%. The company’s shares are currently up 0.49% year-to-date, but still down -0.1287 over the last five days. On the other hand, Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) is 0.37% up in the 30-day period. We can see from the shorts that 4.13 Million shares have been sold at a short interest cover period of 0.81 day(s).
The consensus price target as assigned by Wall Street analysts is $7.42, which translates to bears needing to increase their stock price by 51.12% from its current value. Analyst projections state that ZYNE is forecast to be at a low of $4.5 and a high of $9. In order for the stock price to hit the forecast high, the stock would need to surge +83.3% from its current level, while the stock would need to crash -8.35% from its current level to reach the projected low.
Zynerba Pharmaceuticals, Inc. (ZYNE) projections and forecasts
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -17.8%. Zynerba Pharmaceuticals, Inc. earnings are expected to increase by 42.6% in 2021, but the outlook is negative 0% per year for the next five years.
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE)’s Biggest Investors
Upon looking at major shareholders, it appears that insiders hold 7.11% of Zynerba Pharmaceuticals, Inc. shares, and 22.03% of them are in the hands of institutional investors. The stock currently has a share float of 23.72%. Zynerba Pharmaceuticals, Inc. stock is held by 91 institutions, with Vanguard Group, Inc. (The) being the largest institutional investor. By Sep 29, 2020, it held 3.11% of the shares, which is about 916.57 Thousand shares worth $3.03 Million.
ETF Managers Group, LLC, with 3.03% or 891.03 Thousand shares worth $2.95 Million as of Sep 29, 2020, holds the second largest percentage of outstanding shares.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.